Anti-thymocyte globulin (rabbit) Disease Interactions
There are 2 disease interactions with anti-thymocyte globulin (rabbit).
Anti-thymocyte globulin [rabbit] (applies to anti-thymocyte globulin (rabbit)) infections
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Immunodeficiency, Bone Marrow Depression/Low Blood Counts
The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.
Anti-thymocyte globulin [rabbit] (applies to anti-thymocyte globulin (rabbit)) vaccination
Major Potential Hazard, Moderate plausibility.
Patients recently treated with anti-thymocyte globulin [rabbit] should not receive immunizations with live viral vaccines.
Switch to professional interaction data
Anti-thymocyte globulin (rabbit) drug interactions
There are 167 drug interactions with anti-thymocyte globulin (rabbit).
More about anti-thymocyte globulin (rabbit)
- anti-thymocyte globulin (rabbit) consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.